Host-Defense Peptides Caerin 1.1 and 1.9 Stimulate TNF-Alpha-Dependent Apoptotic Signals in Human Cervical Cancer HeLa Cells

Ni, Guoying; Chen, Shu; Chen, Mo; Wu, Jialing; Yang, Baofeng; Yuan, Jing; Walton, Shelley F.; Li, Hejie; Wei, Ming Q.; Wang, Yuejian; Chen, Guoqiang; Liu, Xiaosong; Wang, Tianfang

doi:10.3389/fcell.2020.00676

Cited by 29 publications

(36 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Total protein was extracted by a previously described method [ 16 ]. Briefly, the protein concentration of F1-treated CAL-62 cells was detected by the BCA method (Thermo Scientific, USA), and the extracts containing equal amounts of proteins (20 μg) were electrophoresed in the desired concentration of polyacrylamide gel according to the size of the target protein and then transferred to a PVDF membrane.…”

Section: Methodsmentioning

confidence: 99%

Targeted radioimmunotherapy with the iodine-131-labeled caerin 1.1 peptide for human anaplastic thyroid cancer in nude mice

Lin

Liu

et al. 2021

Ann Nucl Med

Self Cite

View full text Add to dashboard Cite

Objective The combination of two or more drugs with different mechanisms is a promising strategy for cancer treatment, and radioimmunotherapy (RIT) is a trending antitumor strategy. Radiotherapy (RT) can promote and activate antitumor immune effects, and immunotherapy can strengthen the effects of selective internal radiotherapy (SIRT); the RIT combination is synergistic and can overcome the adverse side effects of monotherapy. In this study, we developed a radioimmunoconjugate (RIC)—the iodine-131 (131I)-labeled caerin 1.1 peptide—to treat human anaplastic thyroid cancer (ATC). Methods Antitumor activity of caerin 1.1 peptide was determined by MTT assay, plate colony formation and cell wound scratch assays, and the mechanism of the inhibition of carein 1.1 peptide on the growth of CAL-62 cells was identified by cell cycle and western blot. Then, we investigated the efficacy of the caerin 1.1 peptide as a single drug and the 131I-labeled caerin 1.1 peptide for ATC. H&E and TUNEL staining was performed to detect dead cells in the tumor tissue sections. Results We found that caerin 1.1 arrested cells in the S phase to induce apoptosis and inhibited tumor growth to inhibit phosphorylation of Akt. In vivo, the iodine-131 (131I)-labeled caerin 1.1 peptide achieved better antitumor efficacy than radiotherapy alone and showed a good biosafety profile. Conclusions Our study demonstrates for the first time that the iodine-131 (131I)-labeled caerin 1.1 peptide can inhibit CAL-62 tumor growth and migration. The iodine-131 (131I)-labeled caerin 1.1 peptide, which represents a radioimmunotherapy strategy based on the combination of SIRT with a peptide–drug conjugate, could provide a treatment means for the radical cure of ATC.

show abstract

Section: Methodsmentioning

confidence: 99%

Targeted radioimmunotherapy with the iodine-131-labeled caerin 1.1 peptide for human anaplastic thyroid cancer in nude mice

Lin

Liu

et al. 2021

Ann Nucl Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…Many of these peptides, including caerin peptides, have antiviral, antitumor, antimicrobial, and/or neuropeptide-type activities (7)(8)(9)(10). Caerin 1.1 has an anti-cancer effect against a number of human cancer cell lines, including leukaemia, lung, colon, CNS, melanoma, ovarian, renal, prostate, and breast cancers (8,11).…”

Section: Introductionmentioning

confidence: 99%

“…Caerin 1.1 and 1.9 inhibit HIV-infected T cells within minutes post-exposure at concentrations non-toxic to T cells and inhibit the transfer of HIV from dendritic cells (DCs) to T cells with limited toxicity (10,16). Recently, it has been shown that Caerin 1.1 and Caerin 1.9 peptides have additive effects against human papillomavirus transformed tumour cells and increase the efficacy of a therapeutic vaccine against HPV related diseases (9,(17)(18)(19).…”

Section: Introductionmentioning

confidence: 99%

Caerin 1.1 and 1.9 peptides from Australian tree frog inhibit antibiotic-resistant bacteria growth in a murine skin infection model

Chen

Zhang

Xiao

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Host-defence caerin 1.9 peptide was originally isolated from skin secretion of Australian tree frog, and inhibits the growth of a wide range of bacteria in vitro. In this study, we demonstrated that caerin 1.9 shows high bioactivity against several bacteria strains, such as Staphylococcus aureus, Acinetobacter Baumannii, methicillin-resistant Staphylococcus aureus (MRSA), and Streptococcus hemolyiicus in vitro. Importantly, unlike antibiotic Tazocin, caerin 1.9 does not induce bacterial resistance after 30 rounds of in vitro culture. Moreover, caerin 1.1, another peptide of caerin family, has additive antibacterial effect when used together with caerin 1.9. Furthermore, caerin 1.1 and 1.9 prepared in the form of a temperature sensitive gel inhibit MRSA growth in skin bacterial infection model of two murine strains. These results indicate that caerin 1.1 and 1.9 may have the advantage than conventional antibiotics against bacterial infection of skin.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Cervical cancer is one of the most common malignancies in women ( Cisse et al, 2019 ; Feng et al, 2019 ; Vliet-Gregg et al, 2019 ; Wang et al, 2020b ), leading to major health problems for high morbidity and mortality ( Li et al, 2019 ; Ni et al, 2020 ; Wang et al, 2020d ; Wu et al, 2020a ). Cervical cancer is mainly caused by the human papilloma virus infection ( Ding et al, 2019 ; Young et al, 2019 ; Cerasuolo et al, 2020 ), and is one of the most common gynecological malignancies, and its incidence rate ranks second among female malignancies in developing countries, and is behind breast cancer ( Cisse et al, 2019 ; Li et al, 2019 ; Ni et al, 2020 ; Wang et al, 2020d ; Wu et al, 2020a ), and its mortality rate ranks third that is behind breast cancer and lung cancer. At present, surgery, radiotherapy, and chemotherapy have a better effect on early cervical cancer ( Hu et al, 2019 ; Harkenrider et al, 2020 ; Rotman et al, 2020 ; Wang et al, 2020a ), which its 5-year survival rates could reach 91.5%, but its efficacy on advanced and metastatic cervical cancers is very limited with its 5-year survival rate is only 17.3% ( Wang et al, 2019 ; Chen et al, 2020 ; Du et al, 2020 ; Zhang et al, 2020b ), meanwhile, the survival rate of recurrent cervical cancer is lower ( Jayamohan et al, 2019 ; Wei et al, 2019 ; Yuan et al, 2019 ; Zhang et al, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

CircAMOTL1 Promotes Tumorigenesis Through miR-526b/SIK2 Axis in Cervical Cancer

Sun

Niu

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

BackgroundCervical cancer is one of the most common malignancies in women, leading to major health problems for its high morbidity and mortality. Numerous studies have demonstrated that circular RNAs (circRNAs) could be participated in the progression of multifarious diseases, especially plentiful carcinomas. CircAMOTL1 (angiomotin-like1, ID: hsa_circ_0004214), which is located on human chromosome 11:9 4532555-94533477, is involved in the occurrence of breast cancer, etc. However, the intrinsic and concrete molecular mechanism of circAMOTL1 in cervical carcinomas remained thoroughly unclear, which was also the bottleneck of circRNAs studies in cancer.MethodsThe relative expression levels of circAMOTL1 and miR-526b in cervical carcinoma patients’ specimens and cervical carcinoma cell lines were detected by RT-qPCR. Through experiments including loss-function and overexpression, the biological effects of circAMOTL1 and miR-526b on the proliferation, migration, apoptosis, and tumorigenicity were explored in cervical carcinomas. Dual luciferase reporter gene analysis, western blot, and other methods were adopted to explore the circAMOTL1 potential mechanism in cervical carcinomas.ResultsIn our experiments, our researches displayed that circAMOTL1 was significantly higher expression in cervical carcinomas specimens and cell lines. Further experiments illustrated that the knockdown of circAMOTL1 could restrain the malignant phenotype, AKT signaling, and epithelial–mesenchymal transition (EMT) of in cervical carcinomas cells. Meanwhile miR-526b was downregulated in cervical carcinomas and even miR-526b could partially reverse circAMOTL1 function in malignant cervical tumor cells. CircAMOTL1 acts as a microRNA (miRNA) sponge that actively regulates the expression of salt-inducible kinase 2 (SIK2) to sponge miR-526b and subsequently increases malignant phenotypes of cervical carcinomas cells. In a word, circAMOTL1 acts a carcinogenic role and miR-526b serves as the opposite function of antioncogene in the cervical carcinoma pathogenesis.ConclusionCircAMOTL1-miR-526b-SIK2 axis referred to the malignant progression and development of cervical carcinomas. CircAMOTL1 expression was inversely correlated with miR-526b and positively correlated with SIK2 mRNA in cervical cancer tissues. Thus, circAMOTL1 exerted an oncogenic role in cervical cancer progression through sponging miR-526b. Taken together, our study revealed that circAMOTL1 acted as an oncogene and probably was a potential therapeutic target for the cervical cancer.

show abstract

Host-Defense Peptides Caerin 1.1 and 1.9 Stimulate TNF-Alpha-Dependent Apoptotic Signals in Human Cervical Cancer HeLa Cells

Cited by 29 publications

References 64 publications

Targeted radioimmunotherapy with the iodine-131-labeled caerin 1.1 peptide for human anaplastic thyroid cancer in nude mice

Targeted radioimmunotherapy with the iodine-131-labeled caerin 1.1 peptide for human anaplastic thyroid cancer in nude mice

Caerin 1.1 and 1.9 peptides from Australian tree frog inhibit antibiotic-resistant bacteria growth in a murine skin infection model

CircAMOTL1 Promotes Tumorigenesis Through miR-526b/SIK2 Axis in Cervical Cancer

Contact Info

Product

Resources

About